Compare
Alector, Inc. vs X4 Pharmaceuticals, Inc vs Editas Medicine, Inc. vs TScan Therapeutics, Inc.
| Latest fiscal year | Alector, Inc. ALEC | X4 Pharmaceuticals, Inc XFOR | Editas Medicine, Inc. EDIT | TScan Therapeutics, Inc. TCRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $21.05M | $35.11M | $40.52M | $10.32M |
| Revenue growth (YoY) | -79.1% | n/m | +25.4% | +266.7% |
| Gross margin | n/a | 83.6% (computed) | n/a | n/a |
| Operating margin | -741.3% | -247.4% | -394.9% | n/m |
| Net margin | -679.2% | -225.6% | -395.0% | n/m |
| Net income | -$142.93M | -$79.20M | -$160.06M | -$129.77M |
| EPS (Diluted) | -$1.39 | -$1.87 | -$1.80 | -$1.00 |
| Operating cash flow | -$184.03M | -$85.62M | -$165.24M | -$135.32M |
| Free cash flow | -$184.07M | -$85.62M | -$165.85M | -$139.73M |
| Cash & equivalents | $65.80M | $217.05M | $146.65M | $152.41M |
| Total assets | $293.24M | $290.46M | $186.53M | $228.79M |
| Total liabilities | $262.59M | $104.17M | $159.25M | $105.67M |
| Shareholders' equity | $30.65M | $186.29M | $27.29M | $123.12M |
| Return on year-end equity | -466.3% | -42.5% | -586.6% | -105.4% |
| Shares outstanding | 110.36M | 90.91M | 97.87M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Alector, Inc. | X4 Pharmaceuticals, Inc | Editas Medicine, Inc. | TScan Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $21.05M Ended 2025-12-31 | $35.11M Ended 2025-12-31 | $40.52M Ended 2025-12-31 | $10.32M Ended 2025-12-31 |
| 1 year earlier | $100.56M Ended 2024-12-31 | $2.56M Ended 2024-12-31 | $32.31M Ended 2024-12-31 | $2.82M Ended 2024-12-31 |
| 2 years earlier | $97.06M Ended 2023-12-31 | $0 Ended 2023-12-31 | $78.12M Ended 2023-12-31 | $21.05M Ended 2023-12-31 |
| 3 years earlier | $133.62M Ended 2022-12-31 | $0 Ended 2022-12-31 | $19.71M Ended 2022-12-31 | $13.54M Ended 2022-12-31 |
| 4 years earlier | $207.09M Ended 2021-12-31 | $0 Ended 2021-12-31 | $25.54M Ended 2021-12-31 | $10.14M Ended 2021-12-31 |